Recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: A model for Canada?

Current Oncology

Volumn 21, Issue 5, 2014, Pages 251-262

  Patel, S ^a   Parliament, M ^a   Kostaras, X ^b   Hagen, N ^b   Olivotto, I A ^c   Nordal, R ^c   Aronyk, K ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Proton beam therapy; Radiation therapy; Recommendations; Review

Indexed keywords

ARTICLE; CANADA; CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD CANCER; CHONDROSARCOMA; CHORDOMA; CHOROID MELANOMA; HEAD AND NECK CANCER; HEALTH CARE COST; HUMAN; PEDIATRICS; PROSTATE CANCER; PROTON THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINOBLASTOMA; RETROSPECTIVE STUDY;

EID: 84907731973     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.2207     Document Type: Article

References (106)

1. Loeffler JS, Durante M. Charged particle therapy-optimization, challenges and future directions. Nat Rev Clin Oncol 2013;10:411-24.
2. Particle Therapy Co-Operative Group (PTCOG). Home > Facilities in Operation [Web page]. Villigen, Switzerland: PTCOG; 2014. [Current version available at: http://www.ptcog.ch/index. php/facilities-in-operation; cited May 25, 2014]
3. Kerstiens J, Johnstone PA. Proton therapy expansion under current United States reimbursement models. Int J Radiat Oncol Biol Phys 2014;89:235-40.
4. TRIUMF. Home > Proton Therapy [Web page]. Vancouver, BC: TRIUMF; n.d. [Available at: http://www.triumf.ca/protontherapy; cited May 25, 2014].
5. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006;65:1-7.
6. Zhang R, Howell RM, Giebeler A, Taddei PJ, Mahajan A, Newhauser WD. Comparison of risk of radiogenic second cancer following photon and proton craniospinal irradiation for a pediatric medulloblastoma patient. Phys Med Biol 2013;58:807-23.
7. Paganetti H. Assessment of the risk for developing a second malignancy from scattered and secondary radiation in radiation therapy. Health Phys 2012;103:652-61.
8. Sethi RV, Shih HA, Yeap BY, et al. Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer 2014;120:126-33.
9. Chung CS, Yock TI, Nelson K, Xu Y, Keating NL, Tarbell NJ. Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys 2013;87:46-52.
10. Bekelman JE, Schultheiss T, Berrington De Gonzalez A. Subsequent malignancies after photon versus proton radiation therapy. Int J Radiat Oncol Biol Phys 2013;87:10-12.
11. St Clair WH, Adams JA, Bues M, et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004;58:727-34.
12. Brodin NP, Munck af Rosenschold P, Blomstrand M, et al. Hippocampal sparing radiotherapy for pediatric medulloblastoma: impact of treatment margins and treatment technique. Neuro Oncol 2014;16:594-602.
13. Blomstrand M, Brodin NP, Munck Af Rosenschold P, et al. Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma. Neuro Oncol 2012;14:882-9.
14. Mailhot Vega RB, Kim J, Bussiere M, et al. Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. Cancer 2013;119:4299-307.
15. Schreiber JE, Gurney JG, Palmer SL, et al. Examination of risk factors for intellectual and academic outcomes following treatment for pediatric medulloblastoma. Neuro Oncol 2014;16:1129-36.
16. Sethi RV, Giantsoudi D, Raiford M, et al. Patterns of failure after proton therapy in medulloblastoma; linear energy transfer distributions and relative biological effectiveness associations for relapses. Int J Radiat Oncol Biol Phys 2014;88:655-63.
17. Boehling NS, Grosshans DR, Bluett JB, et al. Dosimetric comparison of three-dimensional conformal proton radiotherapy, intensity-modulated proton therapy, and intensity-modulated radiotherapy for treatment of pediatric craniopharyngiomas. Int J Radiat Oncol Biol Phys 2012;82:643-52.
18. Beltran C, Roca M, Merchant TE. On the benefits and risks of proton therapy in pediatric craniopharyngioma. Int J Radiat Oncol Biol Phys 2012;82:e281-7.
19. Fitzek MM, Linggood RM, Adams J, Munzenrider JE. Combined proton and photon irradiation for craniopharyngioma: long-term results of the early cohort of patients treated at Harvard Cyclotron Laboratory and Massachusetts General Hospital. Int J Radiat Oncol Biol Phys 2006;64:1348-54.
20. Macdonald SM, Sethi R, Lavally B, et al. Proton radiotherapy for pediatric central nervous system ependymoma: clinical outcomes for 70 patients. Neuro Oncol 2013;15:1552-9.
21. Amsbaugh MJ, Grosshans DR, McAleer MF, et al. Proton therapy for spinal ependymomas: planning, acute toxicities, and preliminary outcomes. Int J Radiat Oncol Biol Phys 2012;83:1419-24.
22. Hoch BL, Nielsen GP, Liebsch NJ, Rosenberg AE. Base of skull chordomas in children and adolescents: a clinicopathologic study of 73 cases. Am J Surg Pathol 2006;30:811-18.
23. Rombi B, Ares C, Hug EB, et al. Spot-scanning proton radiation therapy for pediatric chordoma and chondrosarcoma: clinical outcome of 26 patients treated at Paul Scherrer Institute. Int J Radiat Oncol Biol Phys 2013;86:578-84.
24. Petrovic A, Bergin C, Schalenbourg A, Goitein G, Zografos L. Proton therapy for uveal melanoma in 43 juvenile patients: long-term results. Ophthalmology 2014;121:898-904.
25. MacDonald SM, Trofimov A, Safai S, et al. Proton radiotherapy for pediatric central nervous system germ cell tumors: early clinical outcomes. Int J Radiat Oncol Biol Phys 2011;79:121-9.
26. Hill-Kayser C, Tochner Z, Both S, et al. Proton versus photon radiation therapy for patients with high-risk neuroblastoma: the need for a customized approach. Pediatr Blood Cancer 2013;60:1606-11.
27. Hattangadi JA, Rombi B, Yock TI, et al. Proton radiotherapy for high-risk pediatric neuroblastoma: early outcomes and dose comparison. Int J Radiat Oncol Biol Phys 2012;83:1015-22.
28. Childs SK, Kozak KR, Friedmann AM, et al. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys 2012;82:635-42.
29. Cotter SE, Herrup DA, Friedmann A, et al. Proton radiotherapy for pediatric bladder/prostate rhabdomyosarcoma: clinical outcomes and dosimetry compared to intensitymodulated radiation therapy. Int J Radiat Oncol Biol Phys 2011;81:1367-73.
30. Timmermann B, Schuck A, Niggli F, et al. Spot-scanning proton therapy for malignant soft tissue tumors in childhood: first experiences at the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys 2007;67:497-504.
31. Rombi B, DeLaney TF, MacDonald SM, et al. Proton radiotherapy for pediatric Ewing's sarcoma: initial clinical outcomes. Int J Radiat Oncol Biol Phys 2012;82:1142-8.
32. Hoppe BS, Flampouri S, Zaiden R, et al. Involved-node proton therapy in combined modality therapy for hodgkin lymphoma: results of a phase 2 study. Int J Radiat Oncol Biol Phys 2014;89:1053-9.
33. Merchant TE. Clinical controversies: proton therapy for pediatric tumors. Semin Radiat Oncol 2013;23:97-108.
34. Catton C, O'Sullivan B, Bell R, et al. Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol 1996;41:67-72.
35. Romero J, Cardenes H, la Torre A, et al. Chordoma: results of radiation therapy in eighteen patients. Radiother Oncol 1993;29:27-32.
36. Debus J, Schulz-Ertner D, Schad L, et al. Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base. Int J Radiat Oncol Biol Phys 2000;47:591-6.
37. Masson-Cote L, Bahl G, Atenafu E, Menard C, Millar B, Catton C, et al. High dose photon radiotherapy for skull base chordomas and chondrosarcomas [abstract 1057]. Int J Radiat Oncol Biol Phys 2011;81:S184.
38. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol 1999;175(suppl 2):57-63.
39. Ares C, Hug EB, Lomax AJ, et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys 2009;75:1111-18.
40. McDonald MW, Linton OR, Shah MV. Proton therapy for reirradiation of progressive or recurrent chordoma. Int J Radiat Oncol Biol Phys 2013;87:1107-14.
41. Rieken S, Habermehl D, Nikoghosyan A, et al. Assessment of early toxicity and response in patients treated with proton and carbon ion therapy at the Heidelberg ion therapy center using the raster scanning technique. Int J Radiat Oncol Biol Phys 2011;81:e793-801.
42. Munzenrider JE, Verhey LJ, Gragoudas ES, et al. Conservative treatment of uveal melanoma: local recurrence after proton beam therapy. Int J Radiat Oncol Biol Phys 1989;17:493-8.
43. Munzenrider JE, Gragoudas ES, Seddon JM, et al. Conservative treatment of uveal melanoma: probability of eye retention after proton treatment. Int J Radiat Oncol Biol Phys 1988;15:553-8.
44. Dendale R, Lumbroso-Le Rouic L, Noel G, et al. Proton beam radiotherapy for uveal melanoma: results of Curie Institut- Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys 2006;65:780-7.
45. Caujolle JP, Paoli V, Chamorey E, et al. Local recurrence after uveal melanoma proton beam therapy: recurrence types and prognostic consequences. Int J Radiat Oncol Biol Phys 2013;85:1218-24.
46. Tran E, Ma R, Paton K, Blackmore E, Pickles T. Outcomes of proton radiation therapy for peripapillary choroidal melanoma at the BC Cancer Agency. Int J Radiat Oncol Biol Phys 2012;83:1425-31.
47. Krema H, Somani S, Sahgal A, et al. Stereotactic radiotherapy for treatment of juxtapapillary choroidal melanoma: 3-year follow-up. Br J Ophthalmol 2009;93:1172-6.
48. Dieckmann K, Georg D, Zehetmayer M, Bogner J, Georgopoulos M, Potter R. LINAC based stereotactic radiotherapy of uveal melanoma: 4 years clinical experience. Radiother Oncol 2003;67:199-206.
49. Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 2002;120:1665-71.
50. Gragoudas ES, Lane AM, Regan S, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol 2000;118:773-8.
51. Wilson MW, Hungerford JL. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology 1999;106:1579-87.
52. Marucci L, Ancukiewicz M, Lane AM, Collier JM, Gragoudas ES, Munzenrider JE. Uveal melanoma recurrence after fractionated proton beam therapy: comparison of survival in patients treated with reirradiation or with enucleation. Int J Radiat Oncol Biol Phys 2011;79:842-6.
53. Mizumoto M, Tsuboi K, Igaki H, et al. Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2010;77:98-105.
54. Hattangadi-Gluth JA, Chapman PH, Kim D, et al. Singlefraction proton beam stereotactic radiosurgery for cerebral arteriovenous malformations. Int J Radiat Oncol Biol Phys 2014;89:338-46.
55. Hattangadi JA, Chapman PH, Bussiere MR, et al. Planned two-fraction proton beam stereotactic radiosurgery for highrisk inoperable cerebral arteriovenous malformations. Int J Radiat Oncol Biol Phys 2012;83:533-41.
56. Walcott BP, Hattangadi-Gluth JA, Stapleton CJ, Ogilvy CS, Chapman PH, Loeffler JS. Proton beam stereotactic radiosurgery for pediatric cerebral arteriovenous malformations. Neurosurgery 2014;74:367-74.
57. Weber DC, Schneider R, Goitein G, et al. Spot scanning-based proton therapy for intracranial meningioma: long-term results from the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys 2012;83:865-71.
58. Slater JD, Loredo LN, Chung A, et al. Fractionated proton radiotherapy for benign cavernous sinus meningiomas. Int J Radiat Oncol Biol Phys 2012;83:e633-7.
59. Halasz LM, Bussiere MR, Dennis ER, et al. Proton stereotactic radiosurgery for the treatment of benign meningiomas. Int J Radiat Oncol Biol Phys 2011;81:1428-35.
60. Wenkel E, Thornton AF, Finkelstein D, et al. Benign meningioma: partially resected, biopsied, and recurrent intracranial tumors treated with combined proton and photon radiotherapy. Int J Radiat Oncol Biol Phys 2000;48:1363-70.
61. Bush DA, McAllister CJ, Loredo LN, Johnson WD, Slater JM, Slater JD. Fractionated proton beam radiotherapy for acoustic neuroma. Neurosurgery 2002;50:270-5.
62. Weber DC, Chan AW, Bussiere MR, et al. Proton beam radiosurgery for vestibular schwannoma: tumor control and cranial nerve toxicity. Neurosurgery 2003;53:577-88.
63. Combs SE, Laperriere N, Brada M. Clinical controversies: proton radiation therapy for brain and skull base tumors. Semin Radiat Oncol 2013;23:120-6.
64. Barney CL, Brown AP, Grosshans DR, et al. Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiation. Neuro Oncol 2014;16:303-9.
65. Brown AP, Barney CL, Grosshans DR, et al. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys 2013;86:277-84.
66. Resto VA, Chan AW, Deschler DG, Lin DT. Extent of surgery in the management of locally advanced sinonasal malignancies. Head Neck 2008;30:222-9.
67. Fukumitsu N, Okumura T, Mizumoto M, et al. Outcome of T4 (International Union Against Cancer Staging System, 7th edition) or recurrent nasal cavity and paranasal sinus carcinoma treated with proton beam. Int J Radiat Oncol Biol Phys 2012;83:704-11.
68. Zenda S, Kohno R, Kawashima M, et al. Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys 2011;81:1473-8.
69. Truong MT, Kamat UR, Liebsch NJ, et al. Proton radiation therapy for primary sphenoid sinus malignancies: treatment outcome and prognostic factors. Head Neck 2009;31:1297-308.
70. Ramaekers BL, Pijls-Johannesma M, Joore MA, et al. Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photons, carbon-ions and protons. Cancer Treat Rev 2011;37:185-201.
71. Yu JB, Soulos PR, Herrin J, et al. Proton versus intensitymodulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst 2013;105:25-32.
72. Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995;32:3-12.
73. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010;28:1106-11.
74. Coen JJ, Zietman AL, Rossi CJ, et al. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. Int J Radiat Oncol Biol Phys 2012;82:e25-31.
75. Kim YJ, Cho KH, Pyo HR, et al. A phase II study of hypofractionated proton therapy for prostate cancer. Acta Oncol 2013;52:477-85.
76. Mendenhall NP, Hoppe BS, Nichols RC, et al. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2014;88:596-602.
77. Hoppe BS, Michalski JM, Mendenhall NP, et al. Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer 2014;120:1076-82.
78. Gray PJ, Paly JJ, Yeap BY, et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer 2013;119:1729-35.
79. Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 2012;307:1611-20.
80. Kim S, Shen S, Moore DF, et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur Urol 2011;60:908-16.
81. Murray L, Henry A, Hoskin P, Siebert FA, Venselaar J on behalf of the BRAPHYQS/PROBATE group of the GEC ESTRO. Second primary cancers after radiation for prostate cancer: a review of data from planning studies. Radiat Oncol 2013;8:172.
82. Suit H, Kooy H, Trofimov A, et al. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiother Oncol 2008;86:148-53.
83. Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol 2008;26:175-6.
84. Glatstein E, Glick J, Kaiser L, Hahn SM. Should randomized clinical trials be required for proton radiotherapy? An alternative view. J Clin Oncol 2008;26:2438-9.
85. Wolden SL. Protons for craniospinal radiation: are clinical data important? Int J Radiat Oncol Biol Phys 2013;87:231-2.
86. Sheehan M, Timlin C, Peach K, et al. Position statement on ethics, equipoise and research on charged particle radiation therapy. J Med Ethics 2014;40:572-5.
87. Paganetti H. Range uncertainties in proton therapy and the role of Monte Carlo simulations. Phys Med Biol 2012;57:R99-117.
88. Roelofs E, Engelsman M, Rasch C, et al. Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol 2012;7:165-76.
89. Allen AM, Pawlicki T, Dong L, et al. An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee. Radiother Oncol 2012;103:8-11.
90. Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical practice: current clinical evidence. J Clin Oncol 2007;25:965-70.
91. Olsen DR, Bruland OS, Frykholm G, Norderhaug IN. Proton therapy-a systematic review of clinical effectiveness. Radiother Oncol 2007;83:123-32.
92. De Ruysscher D, Mark Lodge M, Jones B, et al. Charged particles in radiotherapy: a 5-year update of a systematic review. Radiother Oncol 2012;103:5-7.
93. American Society for Radiation Oncology (ASTRO). Model Policies: Proton Beam Therapy (PBT). Fairfax, VA: ASTRO; 2014. [Available online at: https://www.astro.org/uploaded Files/Main_Site/Practice_Management/Reimbursement/ ASTRO%20PBT%20Model%20Policy%20FINAL.pdf; cited June 4, 2014].
94. U.K. National Health Service (NHS), National Commissioning Group for Highly Specialised Services. Guidance for the Referral of Patients Abroad for NHS Proton Treatment. Ver. 2.3. Leeds, U.K.: NHS; 2011.
95. Aarhus University. The Danish National Center for Particle Radiotherapy. Aarhus, Denmark: Aarhus University; 2012. [Available online at: http://www.regionmidtjylland.dk/files/ Aktuelt/Billeder%20til%20web/Småtterier/Det%20 Nationale%20Center%20for%20Partikelterapi%202012.pdf; cited May 25, 2014]
96. Health Council of the Netherlands. Proton Radiotherapy. The Hague, Netherlands: Health Council of the Netherlands; 2009. [Available online at: http://www.gezond heidsraad.nl/ sites/default/files/proton_radio therapy200917E_0.pdf; cited May 25, 2014]
97. Institut national d'excellence en santé et an services sociaux (INESSS). Note informative : La protonthérapie. Quebec City, QC: INESSS; 2010. [Available online at: https://www.inesss. qc.ca/fileadmin/doc/AETMIS/Rapports/Cancer/NI-2010_03_ protontherapie.pdf; cited August 18, 2014]
98. Daartz J, Engelsman M, Paganetti H, Bussiere MR. Field size dependence of the output factor in passively scattered proton therapy: influence of range, modulation, air gap, and machine settings. Med Phys 2009;36:3205-10.
99. Engelsman M, Lu HM, Herrup D, Bussiere M, Kooy HM. Commissioning a passive-scattering proton therapy nozzle for accurate SOBP delivery. Med Phys 2009;36:2172-80.
100. Engelsman M, Schwarz M, Dong L. Physics controversies in proton therapy. Semin Radiat Oncol 2013;23:88-96.
101. Farr JB, Mascia AE, Hsi WC, et al. Clinical characterization of a proton beam continuous uniform scanning system with dose layer stacking. Med Phys 2008;35:4945-54.
102. Rana S, Zeidan O, Ramirez E, Rains M, Gao J, Zheng Y. Measurements of lateral penumbra for uniform scanning proton beams under various beam delivery conditions and comparison to the XiO treatment planning system. Med Phys 2013;40:091708.
103. Zhu XR, Poenisch F, Lii M, et al. Commissioning dose computation models for spot scanning proton beams in water for a commercially available treatment planning system. Med Phys 2013;40:041723.
104. Tessa CL, Berger T, Kaderka R, et al. Characterization of the secondary neutron field produced during treatment of an anthropomorphic phantom with X-rays, protons and carbon ions. Phys Med Biol 2014;59:2111-25.
105. St. Jude Children's Research Hospital (STCRH). STCRH and UF Proton Therapy Institute to begin proton therapy clinical trial [Web article]. Memphis, TN: STCRH; 2009. [Available at: http://www.stjude.org/stjude/v/index.jsp?vgnextoid=ff768c a830ac4210VgnVCM1000001e0215acRCRD; cited May 25, 2014]
106. Statistics Canada. Population by year, by province and territory [Web resource]. Ottawa, ON: Statistics Canada; 2013. [Available at: http://www.statcan.gc.ca/tables-tableaux/sum -som/l01/cst01/demo02a-eng.htm; cited May 25, 2014]